Navigation Links
Optimer Pharmaceuticals to Present at the Canaccord Genuity Annual Growth Conference

SAN DIEGO, Aug. 1, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the Company will present at the Canaccord Genuity Annual Growth Conference on August 10, 2011 at 11:30 a.m. Eastern Time at the InterContinental Hotel in Boston.


A live audio webcast of this presentation will be accessible in the Investors section of the Company's website at Replays of this presentation will be available at the same location for 30 days following the meeting.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and is commercializing DIFICID™ (fidaxomicin) Tablets, an FDA approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has filed a marketing authorization application with the European Medicines Agency for fidaxomicin. Optimer's clinical pipeline includes Pruvel™, a product in the fluoroquinolone class of antibiotics that has completed Phase 3 trials as a treatment for infectious diarrhea. Additional information can be found at

Optimer Pharmaceuticals, Inc.
David Walsey, Vice President, Investor Relations and Corporate Communications

Canale Communications, Inc.
Jason I. Spark, Senior Vice President

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
2. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3. Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
4. Optimer Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. Optimer Pharmaceuticals to Present at Oppenheimer Healthcare Conference
6. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
7. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
8. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
9. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
10. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
11. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... ... the year and one of the premier annual events for pharmaceutical manufacturing: 2015 ... 8–11 November 2015, where ISPE hosted the largest number of attendees in more ...
(Date:11/24/2015)... 24, 2015  Clintrax Global, Inc., a worldwide provider of clinical ... today announced that the company has set a new quarterly earnings ... on quarter growth posted for Q3 of 2014 to Q3 of ... Mexico , with the establishment of an ... --> United Kingdom and Mexico ...
(Date:11/24/2015)... ... ... This fall, global software solutions leader SAP and AdVenture Capital brought together ... their BIG ideas to improve health and wellness in their schools. , Now, the ... title of SAP's Teen Innovator, an all-expenses paid trip to Super Bowl 50, and ...
(Date:11/24/2015)... Massachusetts , November 24, 2015 SHPG ... will participate in the Piper Jaffray 27 th Annual Healthcare ... Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ... , Chief Financial Officer, will participate in the Piper Jaffray 27 ... , NY on Tuesday, December 1, 2015, at 8:30 a.m. ...
Breaking Biology Technology:
(Date:11/18/2015)... , November 18, 2015 ... has published a new market report titled  Gesture Recognition ... and Forecast, 2015 - 2021. According to the report, the global ... and is anticipated to reach US$29.1 bn by 2021, ... North America dominated the ...
(Date:11/17/2015)... November 17, 2015 Paris ... 2015.  --> Paris , qui ... DERMALOG, le leader de l,innovation biométrique, a inventé ... passeports et empreintes sur la même surface de balayage. ... et l,autre pour les empreintes digitales. Désormais, un seul ...
(Date:11/17/2015)... SOUTH EASTON, Mass. , Nov. 17, 2015 /PRNewswire/ ... "Company"), a leader in the development and sale of ... to the worldwide life sciences industry, today announced it ... closing of its $5 million Private Placement (the "Offering"), ... Offering to $4,025,000.  One or more additional closings are ...
Breaking Biology News(10 mins):